Page last updated: 2024-09-04

resiquimod and Body Weight

resiquimod has been researched along with Body Weight in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Angeles Ramos, DM; Burfeind, KG; Coussens, LM; Levasseur, PR; Liudahl, SM; Marks, DL; Maurer, HC; Michaelis, KA; Morgan, TK; Norgard, MA; Olive, KP; Olson, B; Pelz, KR; Sivagnanam, S; Zhu, X	1

Other Studies

1 other study(ies) available for resiquimod and Body Weight

Article	Year
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nature communications, 2019, 10-15, Volume: 10, Issue:1 Topics: Animals; Body Weight; Cachexia; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Eating; Gene Expression; Humans; Imidazoles; Locomotion; Mice; Mice, Knockout; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms; Sequence Analysis, RNA; Survival Rate; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden; Tumor Microenvironment	2019

Article

Year

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.

Nature communications, 2019, 10-15, Volume: 10, Issue:1

Topics: Animals; Body Weight; Cachexia; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Eating; Gene Expression; Humans; Imidazoles; Locomotion; Mice; Mice, Knockout; Pancreatic Intraductal Neoplasms; Pancreatic Neoplasms; Sequence Analysis, RNA; Survival Rate; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Burden; Tumor Microenvironment

2019